Publications of proton high resolution magic angle spinning ( 1 H HRMAS) magnetic resonance spectroscopy (MRS) and its role in identification of metabolic markers for human cancer reported between 2005 and 2009 are reviewed according the anatomic sites of cancer: lung, breast, prostate, brain, colorectal, and cervical. Limited and insufficient screening options for the general public have indicated a need for more advanced tests that can identify and locate cancer at an early stage. 1 H HRMAS MRS is a valuable tool that can elucidate relevant biological metabolite information that is being used to distinguish cancer from benign tissue, and even classify types of tumors. Researchers are working to translate this ex vivo spectroscopy information into an in vivo system that could be implemented in cancer clinics.
Introduction
The development of magnetic resonance (MR) technologies has provided doctors with a non-invasive method to assess human malignancies. In vivo MR, both imaging (MRI) and spectroscopy (MRS), have become invaluable tools in the clinic because of their abilities to distinctly image tissue structures and chemically quantify different metabolisms capable of differentiating between cancerous lesions and normal tissue (1) .
Technical developments for cancer diagnosis and treatment are continuously advancing. However, in the clinic there are still major gaps in knowledge concerning the optimal treatment strategy for individual patients. Realizing the strength of MRS over MRI in revealing the biological activities associated with oncological Technology in Cancer Research & Treatment, Volume 9, Number 4, August 2010 development and progression, researchers of in vivo MRS have advanced the clinical applicability of the technology. In vivo MRS has presented itself as a useful tool that provides supplemental diagnostic information for various malignancies, despite recognized limitations in spectral resolution and the inability to measure individual metabolites (2). These developments together with the emergence of in vivo MR techniques, such as diffusion weighted imaging (3) (4) (5) , and dynamic contrast enhancement (5, 6) have improved tumor localization, and have already been implemented in clinical trials.
In addition to these in vivo investigations and applications, ex vivo studies on human surgical and biopsy specimens have shown the potential of metabolic profiles, as well as individual metabolite levels in connecting insights of tumor biological pathways with improved accuracy in diagnosis of cancer and monitoring of treatment. These studies were inspired by the realization that although histology remains the standard for clinical cancer diagnosis, with many cases it cannot accommodate the requests of differential diagnosis in the era of cancer screening (e.g., mammogram for breast cancer, and prostate specific antigen (PSA) blood tests for prostate cancer). Therefore, more reliable and objective methods for diagnosis are much needed because of the limitations of histopathology ranging from sampling error, to subjective interpretations of pathological characteristics and patterns.
Numerous MRS research efforts are being devoted to attempts of characterizing the general tumor metabolome, as well as that for specific tumor types. In general, tumors are characterized by elevated phospholipid levels (which can be seen as elevation of tCho-total choline containing compounds), increased glycolytic capacity, and high glutaminolytic function (7) . These results have been significant and have the potential to be implemented in clinics to aid in diagnosis and prognosis. However, there are also setbacks. Many other metabolites, including alanine, citrate, glycine, lactate, nucleotides, and lipids vary greatly among distinct tumor types making it difficult to generalize findings (7) . There is also the potential for sampling error, where MRS analysis is prone to the same sampling errors as traditional pathology. Additionally, sample preparation and handling may affect the metabolic data, for example tissue may be contaminated with alcohol that will produce a large peak on that spectrum. Because of these unknowns, metabolic spectroscopy and its use in cancer diagnosis is still in the phase of research. Among these research efforts, and to meet the ex vivo needs, proton high resolution magic angle spinning ( 1 H HRMAS) MRS was developed in the later part of 1990s to improve the resolution of spectra for analysis of intact tissue samples allowing for observation and quantification of individual metabolites, while preserving tissue architectures to allow for subsequent histopathology analysis (8, 9) . Previously, we have extensively reviewed articles published prior to 2005 in the area of applications of the 1 H HRMAS MRS method in human cancer studies (10). In this review, we will focus our attention specifically and only on the use of 1 H HRMAS MRS and its role in cancer diagnosis and prognosis for studies on human samples published after 2005 with the most relevant articles to illustrate this idea. Of another special note and as a general observation we wish to emphasize that since our previous review article and with the maturation of metabolomics and its application in human cancer investigations, recent studies have reported a shift from previous focuses of relationships between individual metabolites and disease, to evaluation of metabolic (metabolomic) profiles. Our reviews below will reflect this phenomenon.
Lung Cancer
Lung cancer, as a major and one of the deadliest human malignancies, is still the leading cause of cancer death among men and women in the U.S. and presents the second highest incidence rates both in men (after prostate cancer) and in women (following breast cancer) (11). The high incidence rate along with high incidence-to-death ratio makes advances in lung cancer early diagnosis and treatment planning absolutely essential for the control of the disease. Unfortunately, at present there is no screening test for lung cancer, and consequently few patients are diagnosed at an early, asymptomatic stage where surgical removal of the tumor can provide a cure. It is thus important for lung cancer researchers to investigate alternative diagnostic methods that would allow for an early diagnosis and a potentially better prognosis. Metabolic profiling using 1 H HRMAS techniques has been investigated in searching for these alternative diagnostic approaches for lung cancer.
A study of 12 cases of human lung cancers, including adenocarcinoma and other mixed tumor types has reported observations of over 50 compounds identified directly through analysis on intact lung tissue using 1 H HRMAS MRS. With the aim of defining the metabolic profiles for lung tumor, the study reported comparisons of metabolomic profiles of tumors with adjacent non-involved tissues. While tumor profiles showed high levels of lipids, phosphocholine (PC), glycerophosphocholine (GPC), creatine and taurine, the profiles for the adjacent non-involved tissue were high in glucose and acetate (12). Principal component analysis (PCA) was applied to verify the significance of this observation, and it was found that the spectral region between 0.5 ppm and 4.75 ppm was best able to clearly distinguish all tumors from the adjacent non-involved samples by principal component 1 (PC1). In contrast, analysis of the low field region was not as sensitive in differentiating tumor from non-involved tissue. Statistical significances were found for elevations of lactate, glucose, PC and GPC in tumor samples when compared with non-involved samples. Additionally, trends were found showing increased levels of creatine, and reduced levels of myo-and scyllo-inositol in tumor samples (12) .
In addition to the search of metabolomic profiles and the investigation of their ability to differentiate cancer from noninvolved tissue with future clinical directions aimed at either in vivo imaging or alternative pathology, metabolomic profiles measured from paired human lung tissue and serum specimens from cancer patients have been studied. Such a study, with the assistance of tissue analyses, was aimed to search for and develop the potential of serum metabolomic markers for lung cancer blood tests. The reported study included matched tissue and serum pairs from patients of squamous cell carcinoma (n = 5) and adenocarcinoma (n = 9), together with seven healthy control serum samples (13) . In this study, all samples including sera were analyzed by 1 H HRMAS MRS. After these MRS analyses, tissue specimens were evaluated by quantitative pathology. Combining data from tissue spectra and pathologies, a metabolomic profile capable of differentiating between the two cancer types was defined. The ability of this profile obtained from tissue analyses to differentiate serum groups (squamous cell carcinoma, adenocarcinoma, healthy control) was tested on the serum spectral data. Furthermore, an additional metabolomic profile was calculated by using cancer patient serum spectral data. Finally, combining the results of these two profiles, the resulting serum discriminator was able to distinguish cancer groups and differentiate them from normal controls with statistical significance (Nominal Logistic Analysis, p < 0.0001), as shown in Figure 1 (13). The visual clustering in Figure 1 that differentiates cancer groups from normal samples was based on the analysis of 21 metabolic regions. The authors also provided the loading factors of these regions for the discriminator, and it is reasonable to assume that higher coefficients correspond to a greater contribution from the changes of that metabolite region in differentiating cancerous samples from normal controls (13). This study presented an extremely important clinical implication of potential lung cancer screening through a blood metabolomic test. After the test, patients with suspicious serum metabolomic profiles will be able to undergo more advanced radiological testing, which would be too expensive to be used as the firstlayer screening tool for the mass public. Thus, serum metabolomic profiles may provide a way for doctors to diagnose lung cancer at an early and asymptomatic stage where effective treatment and a good prognosis are still likely possibilities.
Breast Cancer
Despite all the public awareness, screening implementations, and preventative measures, breast cancer still has the highest incidence rate and is the second leading cause of cancer death among women in the U.S. (11). The largest uncertainty in the breast cancer clinic is the current lack of ability to detect and predict tumor metastatic potential. This lack of knowledge prevents clinicians from providing a comprehensive treatment plan that is the least invasive, and the most effective and beneficial for patients. Screening with annual mammograms for breast cancer has been implemented in many clinics and has increased the incidence of early detection of malignancy (14, 15) . This change of practice, while being essential for successful treatment planning after tumor early detection, has also raised issues that were less encountered previously when diseases were presented with symptoms. Among them, the currently used prognostic factor, lymph-node status, has shown insufficiency in predicting recurrence or metastasis for this screening detected patient population with a 25% false negative rate. A study of breast cancer metabolic profiles obtained from 1 H HRMAS MRS has been reported in the attempt to provide additional biological information that can be critical for more accurate diagnosis and prognosis of breast cancer (16).
Choline metabolites have been studied in relation to various types of cancer due to their altered metabolism in malignant cells. While some choline metabolites, PC and free choline, have shown elevations in tumor samples when compared to adjacent non-involved tissue, GPC results in the most intense choline signal for non-involved tissue. Other metabolites associated with breast cancer also include: creatine, β-glucose, glycine, myo-inositol, and taurine as reported by the study (16). When relative intensities of metabolite peaks, specifically PC, GPC and choline, were compared, researchers of the study lymph nodes. In addition to glycine, taurine has also been found to play an important role in discriminating samples from lymph node positive and lymph node negative patients, although the specific role is of taurine is not known (16). If the above results are proven, the ability of these metabolites to reflect lymph node status would present a needed advance in prognosis for breast cancer patients (16, 17) , allowing clinicians to closely monitor patients with the highest risk for recurrence or metastasis.
Prostate Cancer
Prostate cancer is the most frequently diagnosed form of cancer in males in the U.S., and the second leading cause were able to distinguish tumor (n = 76) from non-involved (n = 9) surgical samples with 82% sensitivity and 100% specificity. Their results also suggested that metabolite concentrations were able to distinguish tumor staging and grading, presenting important information for treatment planning (Figure 2) . Tumors that measured greater than 2.0 cm were found to have significantly increased levels of glycine (p = 0.03) and choline (p = 0.04) when compared to tumors of less than 2.0 cm. The 2.0 cm limit for tumors was chosen by the study because of its role in current pathological tumor staging (16).
Finally, the study shows that elevated levels of glycine were found in large tumors with a high concentration of malignant cells, and are also associated with tumors with positive Figure 2: Spectra of tumor (A) and adjacent non-involved tissue (B) from the same breast cancer patient (number 27) diagnosed with invasive ductal carcinoma, grade II. The spectral region from 5.5 to -0.5 ppm of pulseacquired spectra is shown as A1 and B1. The spectral region from 4.8 to 2.9 ppm from the same spectra is shown as A2 and B2 and the same spectral region (4.8 to 2.9 ppm) from the corresponding spin-echo spectra as A3 and B3. W indicates residual water and L denotes signals from lipids (16). Figure adapted often return false negative results (18, 19) . More advanced tests are needed to provide detailed information of the prostate that can distinguish locations as well as the aggressiveness of tumors in order to direct the most suitable treatment for patients on an individual level.
Multiple studies have shown that individual metabolite levels (20-22), metabolite ratios (23), and metabolomic profiles (24) obtained from 1 H HRMAS spectroscopy are able to of cancer death in men after lung cancer (11). Currently, most prostate cancer cases are detected by annual serum PSA screening tests and subsequent cancer positive biopsies preformed on patients with elevated PSA levels. PSA testing has resulted in a greater percentage of patients diagnosed with prostate cancer at a much earlier stage with likely small lesions. Furthermore, these small lesions of prostate cancer are also known to be heterogeneously distributed in the prostate, thus prostate biopsies preformed on cancer patients can Figure 3 : A, high-resolution magic angle spinning 1 H MR spectrum of intact tissue obtained from the removed prostate of a 61-year-old patient with GS 6 T 2b tumors. Histopathology analysis of the tissue sample (insert) after its spectroscopy measurement revealed that the sample contained 40% histopathologically defined benign epithelium and 60% stromal structures, with no identifiable cancerous glands. Cellular metabolites mentioned in the text are labeled on the spectrum. The 36 most intense resonance peaks or metabolite groups above the horizontal bars were selected for analyses, whereas the other regions were excluded from calculation, partly due to surgery-related alcohol contamination. B, three-dimensional plot of principal component 13 (PC13 correlated linearly with percent volume of cancer cells in tissue samples) versus phosphocholine versus choline. Cancerous and histologically benign (histo-benign) tissue samples from 13 patients can be visually separated in observation plane. The paired Student's t test results (cancer versus histo-benign from the same patients) for principal component 13, phosphocholine, and choline are 0.012, 0.004, and 0.001. Only results from these 13 patients could be evaluated with paired tests for other cancer positive samples were collected from patients from whom no histo-benign samples were analyzed. C, the canonical plot resulting from discriminant analysis of the three variables in B presents the maximum separation between the two groups. D, the resulting receiver operating characteristic curves indicates the accuracy of using the three variables in B to positively identify cancer samples (24). Figure adapted have shown that n-6 PUFA accumulates in malignant tissue samples, but is undetectable in non-malignant samples, suggesting that PUFAs may be used as an additional biomarker to assess tumor aggressiveness. However, the n-6 PUFA did not accumulate in adjacent non-malignant tissue of prostate cancer patients, suggesting that the n-6 PUFA accumulation may be due to tumor growth and not pre-malignant stages of cancer. The n-6 PUFA species detected in this study has not been observed in other MRS studies of prostate cancer (27).
In addition to the spectral technology development by engaging 2D analysis, other technology advancements have also been seen with prostate studies. Ex vivo studies using biopsy or surgical samples most often snap freeze the sample at the time of removal, and may store the samples at -80°C for an extended period of time before analysis. This practice raises the question of whether or not freezing for various amount of time causes metabolic degradation that could affect results. Investigations exploring these questions found that there was no MR detectable metabolic difference between tissue that was snap frozen in the operating room and analyzed within 24 hours, and tissue that was frozen and stored at -80°C for 32 months. Subsequent quantitative pathological analysis from adjacent samples indicated that alterations seen in metabolites may be due to heterogeneous pathologies and not storage conditions (28). In addition to the effects of freezing, the question of optimal spinning speed has also been investigated. In order to best preserve the pathological structures of samples analyzed with 1 H HRMAS MRS it is optimal to use a low spinning speed. However, low spinning speeds result in spinning side bands that must be suppressed to produce an informative spectrum. Research in this area has developed reliable techniques that are able to suppress spinning side bands in the spectrum, while preserving the delicate pathology of tissue samples (29).
Evolving from separately investigating individual metabolites, analysis of prostate cancer metabolomic profiles has presented a global and inclusive evaluation of a large ensemble of metabolites simultaneously as a more efficient paradigm. After studying 199 samples from 82 prostatectomy cases, a study concluded that metabolomic profiles calculated with principal component analysis from 36 metabolite resonances were more sensitive than any single metabolite in differentiating cancerous from histologically benign prostate tissue samples with p < 0.0001 and an overall accuracy of more than 98%. Furthermore, selected principal components, calculated with spectral data from histopathologically benign samples, were also able to distinguish, with statistical significance, between cancers that were prostate confined (stage II), from the ones that invaded extraprostatic tissue (stage III) (24). The latter result was of extreme clinical importance. Currently, due to the inability of radiological imaging to reveal the location and the extent of cancer in the prostate, radical distinguish between cancer and benign samples (Figure 3 ). In addition to improving and eventually implementing tests that are able to detect cancer, studies have also searched for sensitive parameters that can assess tumor aggressiveness beyond the current ability of histopathology. This would provide crucial information for doctors, allowing them to personalize treatment plans and avoid radical treatment in patients with less aggressive tumors that have little chance of the disease spreading or causing much harm. Early detection of prostate cancer has increased the number of patients in this population, which allows for the best prognosis as there are options for non-radical treatments as well as active surveillance (25, 26) .
Lactate and alanine levels have been studied for their potential to predict malignancy of tumors (20, 23) . Prostate biopsy specimens, 82 benign and 16 malignant, were analyzed by 1 H HRMAS MRS to identify metabolites that could serve as biomarkers for distinguishing tumor from benign. Results showed a significant increase in lactate and alanine levels (p  0.0001) in prostate cancer when compared to benign samples. High lactate concentrations have also been associated with more aggressive tumors or metastasis, while lower lactate concentrations have been shown to indicate less aggressive tumors and longer survival. In addition, lactate activates mechanisms that are favorable for metastatic spread, such as activation and upregulation of particular growth factors (20). The above ex vivo work suggests that lactate and alanine as biomarkers of malignancy may translate well into an in vivo system. The ability to assess the malignancy of individual cases would enable doctors to predict the best prognosis and avoid unnecessary treatment. However, this method is still in its infancy with many unknown factors. Limitations have been recognized at a 1.5 T in vivo system, as there have been false positive and false negative results. The use of lactate and alanine could reduce the number of false positives and negatives, and as techniques advance with outer voxel suppression, volume selection, limiting lipid contamination, and increased use of higher field systems (3.0 T) it may be feasible to assess malignancy of individual cases (20).
Studies of the individual levels of choline and ethanolamine
containing metabolites have been linked to the investigations of cancer presence, as well as tumor aggressiveness and therapeutic response. In a two-dimensional (2D) MRS study, total correlation spectroscopy (TOCSY) was found to have better capability to resolve and quantify overlapping peaks of these metabolites when compared to conventional correlation spectroscopy (COSY) (21). Another study used 2D HRMAS techniques to investigate the presence of polyunsaturated fatty acids (PUFAs) in malignant versus non-malignant prostate tissue. Tissue samples (one tumor and two non-malignant per individual) were obtained from 27 prostate cancer patients. It is thought that dietary factors, such as fat (PUFA) intake are related to prostate cancer progression. Preliminary results aggressiveness (31). A similar study compared spectra from in vivo MRS and matched biopsy 1 H HRMAS MRS, and found significant correlations for eight of the twelve metabolites studied (34). These and other similar studies have used 1 H HRMAS MRS as a supplement to better understand in vivo MRS data in hopes of refining and perfecting the use of MRS to non-invasively diagnose brain tumors and provide patients with tailored treatment plans (Figure 4) .
In addition to supplementing in vivo MRS to identify tumors, 1 H HRMAS MRS is being used extensively to study the metabolic differences in tumor type and stage to provide a more complete and reliable diagnosis (36-39). For instance, it is known that histopathological grading of oligodendrogliomas is still controversial, and a more reliable test is needed to improve malignancy grading. 1 H HRMAS MRS and multivariate statistical analyses were used to study biopsy samples histologically classified as low-grade oligodendrogliomas (LGO) n = 6, high-grade oligodendrogliomas (HGO) n = 24, intermediate n = 6, and glioblastomas (GBM) n = 30 (38). The results provided some useful insights into the different metabolic pathways that define malignancy grading. The study also found that tumors could be classified based on a gradient of tumoral hypoxia.
LGOs were found to have the least hypoxia followed sequentially by intermediate oligodendrogliomas, HGOs and GMBs. The metabolomic classification seems to more closely follow patient prognosis when compared to histopathological analysis, making these results very promising as a new, more reliable diagnostic tool (38).
Other studies working to distinguish tumor types have used genomic analysis alongside 1 H HRMAS MRS to analyze potential biomarkers that can facilitate improved tumor typing (40, 41) . Studies have shown that after 1 H HRMAS analysis, tissue mRNA can still be extracted and analyzed. The combined 1 H HRMAS MRS and genomic data (10 control biopsies from epileptic surgeries, and 8 biopsies from anaplastic ganglioma patients) indicated that the altered levels of specific metabolites in CNS tumors directly correspond to altered expression of Kennedy pathway genes, as well as exhibit rapid phospholipid turnover as a result of upregulation of cell proliferation genes (41). The strong correlations found in these results validate the biological relevance of the 1 H HRMAS data. The combined metabolic and genomic approach provides additional information about the biology of anaplastic gangliomas that could be used by neurologists for a better diagnosis, prognosis and overall evaluation of brain tumor patients (41). Additionally, although it has been shown that pathology can be obtained from a tissue sample after spectroscopy analysis (42), this approach has not been reported by any of the studies reviewed here. This is most likely due to the fact that brain tissue is damaged by the high spinning rates used in 1 H HRMAS MRS, and thus pathology is not possible. treatments after a positive biopsy are often proven to be too aggressive resulting in unnecessary morbidities. On the other hand, lack of radical treatments for the aggressive tumors may be dangerously conservative resulting in the advancement of prostate cancer. Unfortunately, for many PSA screening discovered prostate cancer cases, the current pathology is incapable of further addressing the potential aggressiveness of an individual tumor. The result from the aforementioned study suggested that the evaluation of prostate cancer stage may be achieved with metabolomic profile analyses at the time of biopsy, rather than being assigned after prostatectomy, as practiced in the current clinic.
The power of prostate cancer metabolomic profiles has also been demonstrated by a retrospective study of matched prostate cancer samples from patients with or without cancer biochemical recurrence, defined as the increase of blood PSA levels after prostatectomies. The matching of patients according to their clinical and pathological conditions has diminished the power of the currently used monograms in clinics for predicting the potential of tumor recurrence for a particular matched pair of patients. Nevertheless, by using tissue metabolomic profiles the recurrence potential could be predicted with an overall accuracy of 78% (30).
Brain Cancer
There is extensive literature covering the use of in vivo 1 H MRS to detect and diagnose brain tumors. However, this is not due to the prevalence of brain tumors (22,070 predicted new cases resulting in 12,920 deaths, as opposed to the 219,440 new cases of lung cancer resulting in 159,390 deaths (11)), but rather the suitability of MR for the analysis of the brain due to its relative immobility. For brain tumors, in vivo MRS presents an attractive alternative to biopsy, particularly in children, because it is non-invasive and can provide a great deal of metabolic information for diagnosis.
Although in vivo 1 H MRS has demonstrated its advantages and utility in medical imaging, it is still a developing technique, and its further developments rely on a better understanding of brain metabolites. For these reasons, many researchers have engaged in ex vivo 1 H HRMAS MRS analyses to better define and interpret the in vivo observations (31) (32) (33) (34) (35) . The study by Davies et al., looks at the potential of glycine as a biomarker to determine malignancy from in vivo MRS at 1.5 T. Glycine has been neglected as a potential biomarker because of its overlap with myo-inositol and relatively low concentrations in the normal brain. In this study, single-voxel in vivo MRS spectra were analyzed in conjunction with 1 H HRMAS spectra from matched surgical samples. In vivo results were consistent with the 1 H HRMAS results, suggesting that glycine can be reliably detected using in vivo MRS on standard clinical scanners and it is a promising biomarker for tumor 
Other Solid Tumors

Colorectal
Colorectal cancer is common among men and women with a high morbidity and mortality rate (11). Currently, there are tests for early diagnosis of colorectal cancers including fecal occult blood testing (FOBT), sigmoidoscopy (SIG), colonoscopy (COL), and double contrast barium enema (DCBE); however, these tests provide no insight into the biological characteristics of the tumor and thus can hardly be used as prognostic and treatment planning tools. While histopathology from biopsy samples will remain the standard for diagnosis of the diseases, researchers hope that in vivo MRS will eventually be able to non-invasively diagnosis and provide biological information to determine treatment plans in the future.
Studies investigating tumor biopsy samples and matched normal samples with 1 H HRMAS have been able to distinguish malignant from benign tissue (43-45). These studies using 1 H HRMAS MRS to investigate colorectal cancers are currently focused on defining levels of individual metabolites that are characteristic to tumors and are able to distinguish malignant and benign samples. Studies have reported an increase in the metabolites glycine, lactate (42), acetate, taurine, and lipids (43) as characteristics of the colon adenocarcinoma tissues.
Cervical
Cervical intraepithelial neoplasia (CIN) is a well defined pre invasive stage occurring before the onset of cervical cancer. This stage allows researchers to look at biological events in the early phase of malignancy. The ability to characterize CIN as progressing to cancer or possibly remaining benign would be crucial for doctors to suggest treatment plans that are the least invasive possible while resulting in the greatest survival, as well as cost effective.
Researchers have used 1 H and 31 P HRMAS MRS to study metabolite levels that could provide insight into the transition from pre-invasive to invasive cervical cancer (46). The use of 31 P HRMAS MRS was able to provide more detailed information on phosphorylated metabolites (phosphocholine, glycerophosphocholine, phosphoethanolamine, glycerophosphoethanolamine) which have been found to be a good indicator of the presence of tumor. Metabolic results were correlated with histopathology and were able to distinguish between cancerous and normal samples, as well as indicate differences between high grade CIN and cancer in the transition from pre-invasive to invasive disease (46). Although these results are preliminary, there is potential for using metabolic biomarkers to identify the transition between pre-invasive and invasive cervical cancer, which would again allow doctors to provide the best possible treatment on an individual basis.
Conclusions and Future Directions
The use of ex vivo 1 H HRMAS MRS on human cancer specimens can provide invaluable metabolic information to supplement data currently available through in vivo MRS (see Table I for a summary of metabolite changes in tumor samples). At the same time such analyses may supersede the current histopathology, at least for certain types of cancer, by providing previously unavailable biological parameters for an individualized diagnosis. The metabolic information available with this technology is transforming diagnosis and prognosis in oncology clinics, as exemplified by a recent study of metabolomic imaging application for human prostate cancer detection (47). Early detection of malignancy and individualized treatment options are crucial for the control of malignant disease and for increased survival rates. 1 H HRMAS MRS studies reviewed here have demonstrated the potential of the methodology that will deliver promising results to contribute to the development of personalized oncological medicine. 
